Eroom's Law: The Declining Productivity of Drug Discovery

Eroom's Law: The Declining Productivity of Drug Discovery

Eroom's Law, the inverse of Moore's Law, describes the concerning phenomenon of declining productivity in drug development. While Moore's Law observed an exponential growth in computing power over time, Eroom's Law suggests the opposite is happening in pharmaceutical research. Despite advancements in technology and increased investment in research and development (R&D), the number of new drugs approved per billion dollars spent on R&D is steadily declining.

This trend, coined 'Eroom's Law' by researchers in 2012, implies that developing new drugs is becoming increasingly expensive while the rate of successful drug discovery diminishes. The term itself is a clever reversal of 'Moore's Law,' highlighting the stark contrast between these two technological advancements.

The Implications of Eroom's Law

The declining productivity in drug discovery, as described by Eroom's Law, has significant implications for the pharmaceutical industry and healthcare in general. Some of the key concerns include:

• Rising Healthcare Costs: As drug development becomes more expensive, the cost of new medications rises, impacting patient access and affordability.* Stifled Innovation: The increasing difficulty and cost of bringing new drugs to market can discourage investment in research, potentially slowing down progress in critical therapeutic areas.* Longer Development Timelines: The time it takes to bring a new drug from the lab to patients is increasing, delaying potential treatments for various diseases.

Factors Contributing to Eroom's Law

While the exact causes of Eroom's Law are complex and multifaceted, several contributing factors have been proposed:

• Increasing Complexity of Diseases: Researchers are now targeting more complex diseases with multiple underlying mechanisms, making drug development more challenging.* Higher Regulatory Hurdles: The regulatory landscape for drug approvals has become more stringent, requiring more extensive and expensive clinical trials.* Decline in Research Productivity: Despite technological advances, the fundamental process of identifying and validating new drug targets may have become less efficient.

Eroom's Law highlights the pressing need for innovation and efficiency in the pharmaceutical industry. Addressing the factors contributing to declining productivity in drug development is crucial to ensure continued progress in treating diseases and improving human health.